Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · IEX Real-Time Price · USD
44.57
-0.54 (-1.20%)
Apr 24, 2024, 2:35 PM EDT - Market open
Ultragenyx Pharmaceutical Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 - 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|
Cash & Equivalents | 213.58 | 132.94 | 307.58 | 713.53 | 433.58 | 113.43 | 100.49 | 164.61 | 95.85 | 25.07 | Upgrade
|
Short-Term Investments | 363.63 | 614.82 | 432.61 | 488.01 | 321.65 | 346.27 | 134.01 | 219.03 | 343.43 | 163.16 | Upgrade
|
Cash & Cash Equivalents | 577.21 | 747.76 | 740.2 | 1,202 | 755.23 | 459.71 | 234.49 | 383.64 | 439.28 | 188.23 | Upgrade
|
Cash Growth | -22.81% | 1.02% | -38.40% | 59.09% | 64.29% | 96.04% | -38.88% | -12.67% | 133.37% | 249.69% | Upgrade
|
Receivables | 73.39 | 40.45 | 28.43 | 23.09 | 32.84 | 12.74 | 5.17 | 0 | 0 | 0 | Upgrade
|
Inventory | 33.97 | 26.77 | 16.23 | 13.05 | 11.55 | 7.07 | 0.76 | 0 | 0 | 0 | Upgrade
|
Other Current Assets | 47.62 | 68.93 | 71.75 | 57.63 | 51.4 | 42.86 | 29.16 | 18.06 | 10.93 | 5.19 | Upgrade
|
Total Current Assets | 732.18 | 883.9 | 856.6 | 1,295 | 851.02 | 522.37 | 269.58 | 401.7 | 450.21 | 193.42 | Upgrade
|
Property, Plant & Equipment | 290.57 | 259.73 | 176.18 | 114.04 | 74.68 | 20.05 | 21.84 | 17.06 | 7.37 | 3.03 | Upgrade
|
Long-Term Investments | 199.9 | 148.97 | 293.86 | 165.88 | 32.93 | 0 | 9.98 | 117.96 | 99.26 | 0 | Upgrade
|
Goodwill and Intangibles | 210.68 | 204.51 | 175.19 | 175.52 | 173.41 | 173.63 | 185.95 | 0 | 0 | 0 | Upgrade
|
Other Long-Term Assets | 57.69 | 48.34 | 20.56 | 8.81 | 3.47 | 3.51 | 3.41 | 3.91 | 2.73 | 1.52 | Upgrade
|
Total Long-Term Assets | 758.83 | 661.55 | 665.79 | 464.25 | 284.48 | 197.19 | 221.17 | 138.93 | 109.36 | 4.55 | Upgrade
|
Total Assets | 1,491 | 1,545 | 1,522 | 1,760 | 1,135 | 719.56 | 490.75 | 540.63 | 559.57 | 197.97 | Upgrade
|
Accounts Payable | 42.11 | 43.27 | 17.14 | 12.92 | 12.87 | 12.28 | 8.89 | 5.36 | 2.94 | 4.86 | Upgrade
|
Deferred Revenue | 0 | 1.48 | 9.08 | 66.57 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Current Debt | 12.6 | 11.78 | 11.07 | 8.98 | 7.24 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Other Current Liabilities | 225.73 | 204.68 | 144.09 | 101.14 | 83.19 | 62.45 | 62.13 | 54.9 | 24.98 | 7.66 | Upgrade
|
Total Current Liabilities | 280.44 | 261.21 | 181.37 | 189.61 | 103.3 | 74.73 | 71.01 | 60.26 | 27.92 | 12.52 | Upgrade
|
Long-Term Debt | 30.57 | 19.81 | 30.9 | 39.25 | 29.76 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Other Long-Term Liabilities | 904.59 | 911.93 | 387.56 | 376.32 | 348.68 | 35.93 | 36.29 | 6.39 | 0.56 | 0.51 | Upgrade
|
Total Long-Term Liabilities | 935.16 | 931.74 | 418.47 | 415.57 | 378.43 | 35.93 | 36.29 | 6.39 | 0.56 | 0.51 | Upgrade
|
Total Liabilities | 1,216 | 1,193 | 599.84 | 605.18 | 481.73 | 110.65 | 107.3 | 66.65 | 28.48 | 13.02 | Upgrade
|
Total Debt | 43.17 | 31.59 | 41.97 | 48.23 | 36.99 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Debt Growth | 36.64% | -24.72% | -12.97% | 30.37% | - | - | - | - | - | - | Upgrade
|
Retained Earnings | -3,387.66 | -2,781.02 | -2,073.6 | -1,619.58 | -1,433.01 | -1,030.28 | -832.67 | -530.53 | -284.66 | -139.04 | Upgrade
|
Comprehensive Income | 0.65 | -6.57 | -1.4 | 0.69 | -0.15 | -0.63 | -5.68 | 0.91 | -0.87 | -0.17 | Upgrade
|
Shareholders' Equity | 275.41 | 352.49 | 922.56 | 1,154 | 653.76 | 608.91 | 383.45 | 473.97 | 531.09 | 184.95 | Upgrade
|
Net Cash / Debt | 534.04 | 716.17 | 698.23 | 1,153 | 718.24 | 459.71 | 234.49 | 383.64 | 439.28 | 188.23 | Upgrade
|
Net Cash / Debt Growth | -25.43% | 2.57% | -39.46% | 60.57% | 56.24% | 96.04% | -38.88% | -12.67% | 133.37% | 249.69% | Upgrade
|
Net Cash Per Share | 7.26 | 10.24 | 10.30 | 18.95 | 12.69 | 9.24 | 5.52 | 9.69 | 11.94 | 6.55 | Upgrade
|
Working Capital | 451.75 | 622.69 | 675.24 | 1,106 | 747.72 | 447.64 | 198.57 | 341.44 | 422.29 | 180.9 | Upgrade
|
Book Value Per Share | 3.75 | 5.04 | 13.61 | 18.97 | 11.55 | 12.23 | 9.03 | 11.97 | 14.44 | 6.43 | Upgrade
|